Angiosarcoma of the Breast Management and Outcomes

被引:28
作者
Gutkin, Paulina M. [1 ]
Ganjoo, Kristen N. [3 ]
Lohman, Marti [3 ]
von Eyben, Rie [1 ]
Charville, Gregory W. [4 ]
Nazerali, Rahim S. [2 ]
Dirbas, Frederick M. [2 ]
Horst, Kathleen C. [1 ]
机构
[1] Stanford Univ, Dept Radiat Oncol, Sch Med, 875 Blake Wilbur Dr,CC-G221A, Stanford, CA 94305 USA
[2] Stanford Univ, Dept Surg, Sch Med, Stanford, CA 94305 USA
[3] Stanford Univ, Dept Med, Sch Med, Div Med Oncol, Stanford, CA 94305 USA
[4] Stanford Univ, Med Ctr, Dept Pathol, Stanford, CA 94305 USA
来源
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 2020年 / 43卷 / 11期
关键词
angiosarcoma; breast cancer; chemotherapy; mastectomy; radiation therapy; ADJUVANT CHEMOTHERAPY; DISEASE-CONTROL; GEMCITABINE; CANCER; SURGERY; SARCOMA;
D O I
10.1097/COC.0000000000000753
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: Angiosarcoma of the breast is rare and has a poor prognosis. We reviewed our institution's experience with this disease to characterize presentation, identify management patterns, and report outcomes. Methods: Fifty-eight patients with nonmetastatic angiosarcoma were identified from 1998 to 2019 and retrospectively reviewed. Overall survival (OS) and recurrence-free survival (RFS) were calculated using the Kaplan-Meier analysis and log-rank test. Results: The median follow-up was 43.4 months (range: 1.8 to 203.3 mo). Twenty-four patients had primary angiosarcoma (PAS) and 34 patients had secondary angiosarcoma (SAS). Patients with PAS were significantly younger than those with SAS (P0.0001). Mastectomy was the main surgical treatment in our cohort (n=47) and 3 underwent a lumpectomy. The multifocal disease was found in 5/23 patients with PAS and 11/35 patients with SAS. Twenty-eight patients received chemotherapy. Radiation was administered to 13 patients with PAS and 3 patients with SAS. Five-year OS was 73.7% for PAS and 63.5% for SAS. Local recurrence occurred in a greater proportion of patients with margins <5 mm than those with margins >= 5 mm. Chemotherapy did not impact RFS and was not associated with OS in PAS (P=0.35). Those with SAS treated with chemotherapy had significantly greater OS than those who did not receive chemotherapy (P=0.043). Radiation did not significantly influence RFS or OS. Conclusions: Five-year OS was higher than anticipated. Margins >5 mm appear important for local control. Patients with SAS, but not PAS, may achieve improved survival with chemotherapy. National trials using prespecified agents may be needed to identify an optimal chemotherapy regimen for women with SAS.
引用
收藏
页码:820 / 825
页数:6
相关论文
共 21 条
[1]   Primary and secondary breast angiosarcoma: single center report and a meta-analysis [J].
Abdou, Yara ;
Elkhanany, Ahmed ;
Attwood, Kristopher ;
Ji, Wenyan ;
Takabe, Kazuaki ;
Opyrchal, Mateusz .
BREAST CANCER RESEARCH AND TREATMENT, 2019, 178 (03) :523-533
[2]   Neoadjuvant Gemcitabine-Taxane Chemotherapy for Radiation-Induced Angiosarcoma of the Breast: A Case Report [J].
Arnaout, Angel ;
Wedman, Dawn M. ;
El-Sayed, Samy ;
Acharya, Virbala ;
Lad, Shilpa .
BREAST JOURNAL, 2012, 18 (03) :276-278
[3]   Secondary breast angiosarcoma and paclitaxel-dependent prolonged disease control: report of two cases and review of the literature [J].
Gambini, Donatella ;
Visintin, Roberto ;
Locatelli, Elisa ;
Bareggi, Claudia ;
Galassi, Barbara ;
Runza, Letterio ;
Blundo, Concetta ;
Sosnovskikh, Irina ;
Tomirotti, Maurizio .
TUMORI, 2015, 101 (02) :E60-E63
[4]   Clinical outcomes in breast angiosarcoma patients: A rare tumor with unique challenges [J].
Gervais, Mai-Kim ;
Burtenshaw, Sally M. ;
Maxwell, Jessica ;
Dickson, Brendan C. ;
Catton, Charles N. ;
Blackstein, Martin ;
McCready, David ;
Escallon, Jaime ;
Gladdy, Rebecca A. .
JOURNAL OF SURGICAL ONCOLOGY, 2017, 116 (08) :1056-1061
[5]   Primary and Radiation-induced Breast Angiosarcoma Clinicopathologic Predictors of Outcomes and the Impact of Adjuvant Radiation Therapy [J].
Ghareeb, Erica R. ;
Bhargava, Rohit ;
Vargo, John A. ;
Florea, Anca V. ;
Beriwal, Sushil .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2016, 39 (05) :463-467
[6]   Angiosarcomas of the breast - A review of 70 cases [J].
Hodgson, Nicole C. ;
Bowen-Wells, Carol ;
Moffat, Fredrick ;
Franceschi, Dido ;
Avisar, Eli .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2007, 30 (06) :570-573
[7]   Laboratory and clinical evidence of synergistic cytotoxicity of sequential treament with gemcitabine followed by docetaxel in the treatment of sarcoma [J].
Leu, KM ;
Ostruszka, LJ ;
Shewach, D ;
Zalupski, M ;
Sondak, V ;
Biermann, JS ;
Lee, JSJ ;
Couwlier, C ;
Palazzolo, K ;
Baker, LH .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (09) :1706-1712
[8]   Doxorubicin, paclitaxel, and cisplatin based chemotherapy for the treatment of angiosarcoma: Two case reports [J].
Lewcun, Joseph A. ;
Pameijer, Colette ;
Kass, Rena ;
Cream, Leah ;
Hershock, Diane ;
Brooks, Ashton J. ;
Dodge, Daleela G. .
INTERNATIONAL JOURNAL OF SURGERY CASE REPORTS, 2020, 68 :83-87
[9]   Cutaneous Radiation-associated Breast Angiosarcoma Radicality of Surgery Impacts Survival [J].
Li, George Z. ;
Fairweather, Mark ;
Wang, Jiping ;
Orgill, Dennis P. ;
Bertagnolli, Monica M. ;
Raut, Chandrajit P. .
ANNALS OF SURGERY, 2017, 265 (04) :814-820
[10]   Extent of resection and role of adjuvant treatment in resected localized breast angiosarcoma [J].
McClelland, Shearwood, III ;
Hatfield, Jess ;
Degnin, Catherine ;
Chen, Yiyi ;
Mitin, Timur .
BREAST CANCER RESEARCH AND TREATMENT, 2019, 175 (02) :409-418